Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Share-based Compensation: 2013-2024

Historic Share-based Compensation for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to $34.4 million.

  • ImmunityBio's Share-based Compensation rose 18.55% to $8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.1 million, marking a year-over-year decrease of 2.80%. This contributed to the annual value of $34.4 million for FY2024, which is 29.96% down from last year.
  • As of FY2024, ImmunityBio's Share-based Compensation stood at $34.4 million, which was down 29.96% from $49.2 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Share-based Compensation ranged from a high of $57.2 million in FY2021 and a low of $2.2 million during FY2020.
  • Over the past 3 years, ImmunityBio's median Share-based Compensation value was $40.2 million (recorded in 2022), while the average stood at $41.3 million.
  • In the last 5 years, ImmunityBio's Share-based Compensation plummeted by 36.07% in 2020 and then spiked by 2,514.59% in 2021.
  • Yearly analysis of 5 years shows ImmunityBio's Share-based Compensation stood at $2.2 million in 2020, then surged by 2,514.59% to $57.2 million in 2021, then fell by 29.73% to $40.2 million in 2022, then increased by 22.36% to $49.2 million in 2023, then dropped by 29.96% to $34.4 million in 2024.